27 related articles for article (PubMed ID: 31609304)
1. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine.
Walsby E; Pratt G; Shao H; Abbas AY; Fischer PM; Bradshaw TD; Brennan P; Fegan C; Wang S; Pepper C
Oncotarget; 2014 Jan; 5(2):375-85. PubMed ID: 24495868
[TBL] [Abstract][Full Text] [Related]
2. CDK9 inhibition activates innate immune response through viral mimicry.
Yalala S; Gondane A; Poulose N; Liang J; Mills IG; Itkonen HM
FASEB J; 2024 Apr; 38(8):e23628. PubMed ID: 38661032
[TBL] [Abstract][Full Text] [Related]
3. Widespread hypertranscription in aggressive human cancers.
Zatzman M; Fuligni F; Ripsman R; Suwal T; Comitani F; Edward LM; Denroche R; Jang GH; Notta F; Gallinger S; Selvanathan SP; Toretsky JA; Hellmann MD; Tabori U; Huang A; Shlien A
Sci Adv; 2022 Nov; 8(47):eabn0238. PubMed ID: 36417526
[TBL] [Abstract][Full Text] [Related]
4. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.
Hou T; Ray S; Brasier AR
J Biol Chem; 2007 Dec; 282(51):37091-102. PubMed ID: 17956865
[TBL] [Abstract][Full Text] [Related]
5. Defective transcription elongation in a subset of cancers confers immunotherapy resistance.
Modur V; Singh N; Mohanty V; Chung E; Muhammad B; Choi K; Chen X; Chetal K; Ratner N; Salomonis N; Weirauch MT; Waltz S; Huang G; Privette-Vinnedge L; Park JS; Janssen EM; Komurov K
Nat Commun; 2018 Oct; 9(1):4410. PubMed ID: 30353012
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
7. T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
Dow EC; Liu H; Rice AP
J Cell Physiol; 2010 Jul; 224(1):84-93. PubMed ID: 20201073
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase 9 links RNA polymerase II transcription to processing of ribosomal RNA.
Burger K; Mühl B; Rohrmoser M; Coordes B; Heidemann M; Kellner M; Gruber-Eber A; Heissmeyer V; Strässer K; Eick D
J Biol Chem; 2013 Jul; 288(29):21173-21183. PubMed ID: 23744076
[TBL] [Abstract][Full Text] [Related]
9. A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers.
Modur V; Singh N; Muhammad B
J Vis Exp; 2019 Sep; (151):. PubMed ID: 31609304
[TBL] [Abstract][Full Text] [Related]
10. Cellular control of gene expression by T-type cyclin/CDK9 complexes.
Garriga J; Graña X
Gene; 2004 Aug; 337():15-23. PubMed ID: 15276198
[TBL] [Abstract][Full Text] [Related]
11. CDK9: a signaling hub for transcriptional control.
Bacon CW; D'Orso I
Transcription; 2019 Apr; 10(2):57-75. PubMed ID: 30227759
[TBL] [Abstract][Full Text] [Related]
12. The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.
Paparidis NF; Durvale MC; Canduri F
Mol Biosyst; 2017 Jan; 13(2):246-276. PubMed ID: 27833949
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
